FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893245372> ?p ?o ?g. }

• W2893245372 endingPage "2464" @default.
• W2893245372 startingPage "2456" @default.
• W2893245372 abstract "The introduction of novel agents has led to major improvements in clinical outcomes for patients with multiple myeloma. To shorten evaluation times for new treatments, health agencies are currently examining minimal residual disease (MRD) as a surrogate end point in clinical trials. We assessed the prognostic value of MRD, measured during maintenance therapy by next-generation sequencing (NGS). MRD negativity was defined as the absence of tumor plasma cell within 1 000 000 bone marrow cells (<10-6). Data were analyzed from a recent clinical trial that evaluated the role of transplantation in newly diagnosed myeloma patients treated with lenalidomide, bortezomib, and dexamethasone (RVD). MRD negativity was achieved at least once during maintenance in 127 patients (25%). At the start of maintenance therapy, MRD was a strong prognostic factor for both progression-free survival (adjusted hazard ratio, 0.22; 95% confidence interval, 0.15-0.34; P < .001) and overall survival (adjusted hazard ratio, 0.24; 95% confidence interval, 0.11-0.54; P = .001). Patients who were MRD negative had a higher probability of prolonged progression-free survival than patients with detectable residual disease, regardless of treatment group (RVD vs transplant), cytogenetic risk profile, or International Staging System disease stage at diagnosis. These results were similar after completion of maintenance therapy. Our findings confirm the value of MRD status, as determined by NGS, as a prognostic biomarker in multiple myeloma, and suggest that this approach could be used to adapt treatment strategies in future clinical trials." @default.
• W2893245372 created "2018-10-05" @default.
• W2893245372 creator A5002061358 @default.
• W2893245372 creator A5002571777 @default.
• W2893245372 creator A5003294000 @default.
• W2893245372 creator A5005242998 @default.
• W2893245372 creator A5011827756 @default.
• W2893245372 creator A5016941619 @default.
• W2893245372 creator A5020996390 @default.
• W2893245372 creator A5021139263 @default.
• W2893245372 creator A5025996929 @default.
• W2893245372 creator A5026625329 @default.
• W2893245372 creator A5026970655 @default.
• W2893245372 creator A5027311948 @default.
• W2893245372 creator A5030565933 @default.
• W2893245372 creator A5030991437 @default.
• W2893245372 creator A5032464400 @default.
• W2893245372 creator A5032939246 @default.
• W2893245372 creator A5038795221 @default.
• W2893245372 creator A5043526996 @default.
• W2893245372 creator A5043695215 @default.
• W2893245372 creator A5044362040 @default.
• W2893245372 creator A5045740077 @default.
• W2893245372 creator A5048560248 @default.
• W2893245372 creator A5054118827 @default.
• W2893245372 creator A5056395107 @default.
• W2893245372 creator A5058532201 @default.
• W2893245372 creator A5059590275 @default.
• W2893245372 creator A5062550034 @default.
• W2893245372 creator A5064631593 @default.
• W2893245372 creator A5064803767 @default.
• W2893245372 creator A5069447323 @default.
• W2893245372 creator A5069745915 @default.
• W2893245372 creator A5070014603 @default.
• W2893245372 creator A5071589084 @default.
• W2893245372 creator A5077081397 @default.
• W2893245372 creator A5079283579 @default.
• W2893245372 creator A5081357051 @default.
• W2893245372 creator A5082698003 @default.
• W2893245372 creator A5083854975 @default.
• W2893245372 creator A5087052731 @default.
• W2893245372 creator A5089853890 @default.
• W2893245372 date "2018-12-06" @default.
• W2893245372 modified "2023-10-18" @default.
• W2893245372 title "Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma" @default.
• W2893245372 cites W1963342145 @default.
• W2893245372 cites W1969648097 @default.
• W2893245372 cites W1985864219 @default.
• W2893245372 cites W2003664440 @default.
• W2893245372 cites W2025013606 @default.
• W2893245372 cites W2048954647 @default.
• W2893245372 cites W2086595383 @default.
• W2893245372 cites W2090310344 @default.
• W2893245372 cites W2110608811 @default.
• W2893245372 cites W2120474651 @default.
• W2893245372 cites W2139260559 @default.
• W2893245372 cites W2144588669 @default.
• W2893245372 cites W2169046713 @default.
• W2893245372 cites W2313577290 @default.
• W2893245372 cites W2343386476 @default.
• W2893245372 cites W2486629951 @default.
• W2893245372 cites W2513443919 @default.
• W2893245372 cites W2518827451 @default.
• W2893245372 cites W2528329272 @default.
• W2893245372 cites W2579739608 @default.
• W2893245372 cites W2604776612 @default.
• W2893245372 cites W2613844594 @default.
• W2893245372 cites W4252175385 @default.
• W2893245372 doi "https://doi.org/10.1182/blood-2018-06-858613" @default.
• W2893245372 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6284215" @default.
• W2893245372 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30249784" @default.
• W2893245372 hasPublicationYear "2018" @default.
• W2893245372 type Work @default.
• W2893245372 sameAs 2893245372 @default.
• W2893245372 citedByCount "276" @default.
• W2893245372 countsByYear W28932453722018 @default.
• W2893245372 countsByYear W28932453722019 @default.
• W2893245372 countsByYear W28932453722020 @default.
• W2893245372 countsByYear W28932453722021 @default.
• W2893245372 countsByYear W28932453722022 @default.
• W2893245372 countsByYear W28932453722023 @default.
• W2893245372 crossrefType "journal-article" @default.
• W2893245372 hasAuthorship W2893245372A5002061358 @default.
• W2893245372 hasAuthorship W2893245372A5002571777 @default.
• W2893245372 hasAuthorship W2893245372A5003294000 @default.
• W2893245372 hasAuthorship W2893245372A5005242998 @default.
• W2893245372 hasAuthorship W2893245372A5011827756 @default.
• W2893245372 hasAuthorship W2893245372A5016941619 @default.
• W2893245372 hasAuthorship W2893245372A5020996390 @default.
• W2893245372 hasAuthorship W2893245372A5021139263 @default.
• W2893245372 hasAuthorship W2893245372A5025996929 @default.
• W2893245372 hasAuthorship W2893245372A5026625329 @default.
• W2893245372 hasAuthorship W2893245372A5026970655 @default.
• W2893245372 hasAuthorship W2893245372A5027311948 @default.
• W2893245372 hasAuthorship W2893245372A5030565933 @default.
• W2893245372 hasAuthorship W2893245372A5030991437 @default.
• W2893245372 hasAuthorship W2893245372A5032464400 @default.
• W2893245372 hasAuthorship W2893245372A5032939246 @default.

• next